Literature DB >> 27377454

IgG4 autoantibodies are inhibitory in the autoimmune disease bullous pemphigoid.

Yagang Zuo1, Flor Evangelista2, Donna Culton2, Antonio Guilabert3, Lin Lin2, Ning Li2, Luis Diaz2, Zhi Liu4.   

Abstract

The IgG4 subclass of antibodies exhibits unique characteristics that suggest it may function in an immunoregulatory capacity. The inhibitory function of IgG4 has been well documented in allergic disease by the demonstration of IgG4 blocking antibodies, but similar functions have not been explored in autoimmune disease. Bullous pemphigoid (BP) is a subepidermal autoimmune blistering disease characterized by autoantibodies directed against BP180 and an inflammatory infiltrate including eosinophils and neutrophils. Animal models have revealed that the NC16A region within BP180 harbors the critical epitopes necessary for autoantibody mediated disease induction. BP180 NC16A-specific IgG belong to the IgG1, IgG3, and IgG4 subclasses. The purpose of this study was to determine effector functions of different IgG subclasses of NC16A-specific autoantibodies in BP. We find that IgG4 anti-NC16A autoantibodies inhibit the binding of IgG1 and IgG3 autoantibodies to the NC16A region. Moreover, IgG4 anti-NC16A blocks IgG1 and IgG3 induced complement fixation, neutrophil infiltration, and blister formation clinically and histologically in a dose-dependent manner following passive transfer to humanized BP180-NC16A mice. These findings highlight the inhibitory role of IgG4 in autoimmune disease and have important implications for the treatment of BP as well as other antibody mediated inflammatory and autoimmune diseases.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Autoimmune; Bullous pemphigoid; IgG4; Inhibitory

Mesh:

Substances:

Year:  2016        PMID: 27377454      PMCID: PMC5003671          DOI: 10.1016/j.jaut.2016.06.019

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  44 in total

1.  Bullous pemphigoid suggestive of complement-independent blister formation with anti-BP180 IgG4 autoantibodies.

Authors:  T Dainichi; W Nishie; Y Yamagami; H Sonobe; H Ujiie; Y Kaku; K Kabashima
Journal:  Br J Dermatol       Date:  2016-03-18       Impact factor: 9.302

Review 2.  IgG4-related disease: nomenclature, clinical features, and treatment.

Authors:  John H Stone
Journal:  Semin Diagn Pathol       Date:  2012-11       Impact factor: 3.464

3.  Subclass distribution of IgG autoantibodies in bullous pemphigoid.

Authors:  P Bird; P S Friedmann; N Ling; A G Bird; R A Thompson
Journal:  J Invest Dermatol       Date:  1986-01       Impact factor: 8.551

4.  Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the BP180 ectodomain.

Authors:  G J Giudice; D J Emery; B D Zelickson; G J Anhalt; Z Liu; L A Diaz
Journal:  J Immunol       Date:  1993-11-15       Impact factor: 5.422

5.  Nonenzymatic glycosylation of immunoglobulin G impairs complement fixation.

Authors:  P J Hennessey; C T Black; R J Andrassy
Journal:  JPEN J Parenter Enteral Nutr       Date:  1991 Jan-Feb       Impact factor: 4.016

6.  Isolation of a human epidermal cDNA corresponding to the 180-kD autoantigen recognized by bullous pemphigoid and herpes gestationis sera. Immunolocalization of this protein to the hemidesmosome.

Authors:  L A Diaz; H Ratrie; W S Saunders; S Futamura; H L Squiquera; G J Anhalt; G J Giudice
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

7.  Role of FcRs in animal model of autoimmune bullous pemphigoid.

Authors:  Minglang Zhao; Mary E Trimbeger; Ning Li; Luis A Diaz; Steven D Shapiro; Zhi Liu
Journal:  J Immunol       Date:  2006-09-01       Impact factor: 5.422

8.  Species-specific determinants in the IgG CH3 domain enable Fab-arm exchange by affecting the noncovalent CH3-CH3 interaction strength.

Authors:  Aran F Labrijn; Theo Rispens; Joyce Meesters; Rebecca J Rose; Tamara H den Bleker; Stefan Loverix; Ewald T J van den Bremer; Joost Neijssen; Tom Vink; Ignace Lasters; Rob C Aalberse; Albert J R Heck; Jan G J van de Winkel; Janine Schuurman; Paul W H I Parren
Journal:  J Immunol       Date:  2011-08-12       Impact factor: 5.422

9.  The serpin alpha1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo.

Authors:  Z Liu; X Zhou; S D Shapiro; J M Shipley; S S Twining; L A Diaz; R M Senior; Z Werb
Journal:  Cell       Date:  2000-09-01       Impact factor: 41.582

10.  IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura.

Authors:  S Ferrari; G C Mudde; M Rieger; A Veyradier; J A Kremer Hovinga; F Scheiflinger
Journal:  J Thromb Haemost       Date:  2009-08-11       Impact factor: 5.824

View more
  15 in total

Review 1.  BP180 Is Critical in the Autoimmunity of Bullous Pemphigoid.

Authors:  Yale Liu; Liang Li; Yumin Xia
Journal:  Front Immunol       Date:  2017-12-08       Impact factor: 7.561

2.  Dysregulation of mCD46 and sCD46 contribute to the pathogenesis of bullous pemphigoid.

Authors:  Pei Qiao; Erle Dang; Tianyu Cao; Hui Fang; Jieyu Zhang; Hongjiang Qiao; Gang Wang
Journal:  Sci Rep       Date:  2017-03-10       Impact factor: 4.379

Review 3.  Bullous pemphigoid.

Authors:  Denise Miyamoto; Claudia Giuli Santi; Valéria Aoki; Celina Wakisaka Maruta
Journal:  An Bras Dermatol       Date:  2019-05-09       Impact factor: 1.896

4.  Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180.

Authors:  Yosuke Mai; Wataru Nishie; Kentaro Izumi; Hiroshi Shimizu
Journal:  Front Immunol       Date:  2019-05-29       Impact factor: 7.561

5.  Levels of serum IgG subclasses in patients with liver disease: A retrospective study.

Authors:  Wei Zheng; Feifei Jiang; Jing Shan; Ying Wang; Yongmei Jia; Qiuyan Guo; Jinli Lou; Yan Zhao
Journal:  Exp Ther Med       Date:  2020-11-17       Impact factor: 2.447

Review 6.  Risk Factors for Mucosal Involvement in Bullous Pemphigoid and the Possible Mechanism: A Review.

Authors:  Xinyi Chen; Wenlin Zhao; Hongzhong Jin; Li Li
Journal:  Front Med (Lausanne)       Date:  2021-05-20

7.  Potential of Murine IgG1 and Human IgG4 to Inhibit the Classical Complement and Fcγ Receptor Activation Pathways.

Authors:  Gina-Maria Lilienthal; Johann Rahmöller; Janina Petry; Yannic C Bartsch; Alexei Leliavski; Marc Ehlers
Journal:  Front Immunol       Date:  2018-05-09       Impact factor: 7.561

8.  Thymic Stromal Lymphopoietin Is Implicated in the Pathogenesis of Bullous Pemphigoid by Dendritic Cells.

Authors:  Si-Zhe Li; Xin-Xing Jin; Xiao-Lei Ge; Ya-Gang Zuo; Hong-Zhong Jin
Journal:  J Immunol Res       Date:  2020-09-24       Impact factor: 4.818

9.  Low serum IgG4 level: a potential diagnostic biomarker for IgA nephropathy.

Authors:  Xinyu Tian; Zhuan Cui; Song Wang; Yuejuan Pan; A Lata; Xinxin Chen; Xiaoxiao Wang; Xiaoyan Qiu; Zhenling Deng; Yue Wang
Journal:  Ann Transl Med       Date:  2021-05

Review 10.  Thymic Stromal Lymphopoietin in Cutaneous Immune-Mediated Diseases.

Authors:  Si-Hang Wang; Ya-Gang Zuo
Journal:  Front Immunol       Date:  2021-06-24       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.